Long-Term Efficacy and Safety of Entrectinib in
Entrectinib
Intracranial efficacy
NSCLC
ROS1 fusions
Treatment post-crizotinib
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
21
04
2022
accepted:
22
04
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Entrectinib is an approved tyrosine kinase inhibitor (TKI) for Adults with The efficacy-assessable population comprised 168 ROS1 TKI-naïve patients. The median survival follow-up was 29.1 months (interquartile range, 21.8-35.9). The ORR was 68% (95% confidence interval [CI]: 60.2-74.8); the median DoR was 20.5 months. The median progression-free survival (PFS) was 15.7 months and the median OS was 47.8 months. In the 25 patients with measurable baseline CNS metastases, the intracranial ORR was 80% (95% CI: 59.3-93.2), median intracranial DoR was 12.9 months, and median intracranial PFS was 8.8 months. Among 18 patients with CNS-only progression on previous crizotinib treatment, two achieved a partial response (11%) and four had stable disease (22%). In seven patients with measurable CNS disease from this cohort, the intracranial ORR was 14% (1 partial response). Entrectinib is active and achieves prolonged survival in ROS1 TKI-naïve patients with
Identifiants
pubmed: 35663414
doi: 10.1016/j.jtocrr.2022.100332
pii: S2666-3643(22)00056-X
pmc: PMC9160474
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100332Informations de copyright
© 2022 The Authors.
Références
J Clin Oncol. 2012 Mar 10;30(8):863-70
pubmed: 22215748
Mol Oncol. 2022 May;16(10):2000-2014
pubmed: 35338679
Clin Cancer Res. 2013 Aug 1;19(15):4040-5
pubmed: 23719267
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii23-viii30
pubmed: 31738426
Ann Oncol. 2020 Sep;31(9):1207-1215
pubmed: 32422171
J Med Chem. 2016 Apr 14;59(7):3392-408
pubmed: 27003761
J Clin Oncol. 2011 May 20;29(15):e443-5
pubmed: 21422405
Mol Cancer Ther. 2016 Apr;15(4):628-39
pubmed: 26939704
Lancet Oncol. 2019 Dec;20(12):1691-1701
pubmed: 31669155
Lung Cancer. 2001 May;32(2):129-36
pubmed: 11325483
Lancet Oncol. 2020 Feb;21(2):261-270
pubmed: 31838015
Oncotarget. 2017 Jun 8;8(32):53336-53351
pubmed: 28881815
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2021 Apr 10;39(11):1253-1263
pubmed: 33646820
Neuro Oncol. 2020 Jun 9;22(6):819-829
pubmed: 32383735
Lancet Oncol. 2020 Feb;21(2):271-282
pubmed: 31838007
J Clin Oncol. 2015 Mar 20;33(9):992-9
pubmed: 25667280
J Clin Oncol. 2018 May 10;36(14):1405-1411
pubmed: 29596029
J Clin Oncol. 2017 Aug 10;35(23):2613-2618
pubmed: 28520527
JTO Clin Res Rep. 2020 Oct 21;2(1):100108
pubmed: 34589973
J Thorac Oncol. 2018 Nov;13(11):1717-1726
pubmed: 29981925
Nat Rev Clin Oncol. 2021 Jan;18(1):35-55
pubmed: 32760015
Ann Oncol. 2019 Jul 1;30(7):1121-1126
pubmed: 30980071
JCO Precis Oncol. 2017;2017:
pubmed: 29333528